Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Method for the production of human immunodeficiency virus (HIV) proteins utilizing modified vaccinia virus ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs)

Method for the production of human immunodeficiency virus (HIV) proteins utilizing modified vaccinia virus ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs)

US Patent 8197822 · Granted Jun 12, 2012

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Immune modulation2021
Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RS2021
Vector-based attenuated poxvirus vaccines2021
Viral vector manufacture2020
Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RS2020
Automated specimen processing systems and multistep processing of microscope sli2019
Recombinant modified vaccinia virus Ankara (MVA) Respiratory Syncytial Virus (RS2018
Poxviral vectors for low antibody response after a first priming immunization2018
Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RS2017
Single high dose of MVA induces a protective immune response in neonates and inf2017
Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RS2016
Recombinant poxvirus vector comprising tetanus toxin fragment C2016